SummaryIn a series of 38 patients treated for advanced Hodgkin’s disease with the MOPP combination chemotherapy of DeVita, Serpick and Carbone, the complete remission rate was 84%. In this series 1/4 of the patients had been previously treated with other methods. Most of them, with a relapse of their disease, had a larger extension of their disease in comparison with the initial stage.In the evaluation of complete remission, the persistence of a splenomegaly (3 patients) is not necessarily a sign of incomplete remission; the histological study of the three spleens demonstrated no involvement of Hodgkin’s disease.The treatment is generally well tolerated. For the whole group, no more than an average decrease of 10 to 15% of the theoretical dose, mainly of the alkylating agents, was applied. The decrease was more important in patients who didn’t respond to the treatment; this allows us to suppose that haematological intolerance is a factor in bad prognosis.With a view to determining the best therapy for maintenance of complete remission, the patients were randomized, once complete remission had been obtained, into four groups, each receiving a different therapy.